ADAPY · Adaptimmune Therapeutics PLC · Executive Compensation
$0.03
+0.00 (+11.30%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
Volume · Oct 20
80.26K
Avg daily vol (3M)
144.54K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Bertrand | Chief Operating Officer | $1,215,100 |
| Helen Tayton-Martin | Chief Business & Strategy Officer | $1,183,352 |
| Elliot Norry | Chief Medical Officer | $1,180,968 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Elliot Norry | Chief Medical Officer | $1,770,746 |
| William Bertrand | Chief Operating Officer | $1,388,271 |
| Helen Tayton-Martin | Chief Business & Strategy Officer | $1,360,293 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer | $4,215,001 |
| William Bertrand | Chief Operating Officer | $1,756,188 |
| Gavin Wood | Chief Financial Officer | $1,756,059 |
| Helen Tayton-Martin | Chief Business & Strategy Officer | $1,738,652 |
| John Lunger | Chief Operating Officer | $1,715,009 |
| Elliot Norry | Chief Medical Officer | $1,710,993 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer | $2,701,602 |
| Gavin Wood | Chief Financial Officer | $1,562,758 |
| Helen Tayton-Martin | Chief Business Officer | $1,555,050 |
| William Bertrand | Chief Operating Officer | $1,551,113 |
| John Lunger | Chief Operating Officer | $1,487,463 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer | $2,155,042 |
| William Bertrand | Chief Operating Officer | $1,371,180 |
| Helen Tayton-Martin | Chief Business Officer | $1,365,277 |
| John Lunger | Chief Operating Officer | $932,610 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Hill | Chief Financial Officer | Appointed | 2025-09-08 |
| John Lunger | Chief Patient Supply Officer | Terminated | 2025-08-29 |
| Gavin Wood | Chief Financial Officer | Terminated | 2025-08-29 |
| Cintia Piccina | Chief Commercial Officer | Terminated | 2025-08-15 |
| Gavin Wood | Chief Financial Officer | Terminated | 2025-08-07 |
| Joanna Brewer | Chief Scientific Officer | Terminated | 2025-08-07 |
| Elliot Norry | Chief Medical Officer | Terminated | 2025-08-07 |
| Gavin Wood | Chief Financial Officer | Resigned | 2025-07-28 |
| Joanna Brewer | Chief Scientific Officer | Resigned | 2025-07-28 |
| Cintia Piccina | Chief Commercial Officer | Resigned | 2025-07-28 |
| Elliot Norry | Chief Medical Officer | Resigned | 2025-07-28 |
| Gavin Wood | Chief Financial Officer | Terminated | 2024-12-19 |
| Dr. Helen Tayton-Martin | Chief Business & Strategy Officer | Terminated | 2024-12-19 |
| Cintia Piccina | Chief Commercial Officer ("CCO") | Appointed | 2024-02-27 |
| Dr. Elliott Sigal | member of the Board of Directors | Resigned | 2023-11-03 |
| Priti Hegde | non-executive director and as a member of the Corporate Governance and Nominating Committee | Appointed | 2023-06-01 |
| Garry Menzel | non-executive director and to serve as a member of the Board's Audit Committee | Appointed | 2023-06-01 |
| Priti Hegde | member of the Board's Corporate Governance and Nominating Committee | Appointed | 2023-06-01 |
| Andrew Allen | member of the Board's Remuneration Committee | Appointed | 2023-06-01 |
| Andrew Allen | non-executive director | Appointed | 2023-06-01 |
| Garry E. Menzel | director | Appointed | 2023-06-01 |
| Priti Hegde | director | Appointed | 2023-06-01 |
| Andrew R. Allen | director | Appointed | 2023-06-01 |
| James Noble | director | Resigned | 2023-06-01 |
| Barbara Duncan | director | Resigned | 2023-06-01 |
Leadership
- Adrian Rawcliffe CEO, Board Member
- David M. Mott Chairman
- Christopher Hill CFO
- William Bertrand COO
- Ali Behbahani Board Member
- Andrew Allen Board Member
- Andrew Allen, MD, PhD Board Member
- Andrew R. Allen Board Member
- Dr Priti Hegde Board Member
- Garry E. Menzel Board Member
- Garry Menzel Board Member
- John Furey Board Member
- Kristen Hege Board Member
- Kristen Hege, M.D. Board Member
- Kristen M. Hege Board Member
- Lawrence M. Alleva Board Member
- Priti Hegde Board Member